Mastodon Skip to main content

Jing Medicine has submitted the IND application for HJ-002-03

 Jing Medicine (和径医药) has submitted the IND application for HJ-002-03, an EGFR-PROTAC, intended for patients with non-small cell lung cancer in China. HJ-002 is the first PROTAC in the IND stage developed by Jing Medicine.

https://doi.org/10.1016/j.ejmech.2022.114533
https://doi.org/10.1016/j.ejmech.2022.114533

In 2022, Jing Medicine received IND approval for HJM-353, an EED inhibitor, in both China and the United States, however, no clinical study has been initiated as of yet.

In 2021, Jing Medicine filed a patent (WO2022268229) claiming the PROTACs targeting EGFR, ALK, and ROS1.  These CRBN-based PROTACs, designed with Brigatinib analogs that target ALK and EGFR kinases, may offer a potential new approach for treating lung cancer by inducing targeted protein degradation. 

Brigatinib and Embodiments in the Patent
Brigatinib and Embodiments in the Patent

E95 and E123 demonstrated potent degradation activity, with DC50 values around single-digit nM and achieving over 90% degradation (Dmax) for EGFR-DTC (Del19/T790M/C797S), EGFR-LTC (EGFR L858R/T790M/C797S), and EGFR-DC (EGFR Del19/C797S).

DC50 and Dmax
DC50 and Dmax

In 2018, Jing Medicine secured a worldwide licensing agreement with ShanghaiTech University for 6 PROTAC degrader drug candidates, with a total package exceeding $100 million.

-------------------------------------
In May 2023, Betta Pharmaceuticals licensed the development and commercialization rights of CFT8919, an EGFR-targeting PROTAC, in Greater China from C4 Therapeutics for an upfront payment of $10 million and a $25 million equity investment.C4 Therapeutics confirmed that Betta will initiate the Phase 1 clinical trial for CFT8919 in China, supporting future global studies of the drug.

In March 2023, Haisco received Investigational New Drug (IND) approval for HSK40118 in patients with advanced non-small cell lung cancer (NSCLC). The clinical trial (NCT06050980) was initiated in China the same month, with an estimated enrollment of around 220 patients.

Comments